Pharmaceutical Technology

JULY 28, 2025

CAGR is largely attributed to the launch of novel biologics and small molecules. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmaceutical Technology

JULY 29, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmaceutical Technology

JULY 29, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

FDA

Pharmaceutical Technology

JULY 22, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

FDA

Pharmaceutical Technology

JULY 21, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmacy Times

AUGUST 1, 2025

PBMs are more powerful and influential than ever as they become extensions of major health insurers, acquire independent pharmacies, and create new business lines to funnel prescriptions through. Today, the 3 largest PBMs control 80% of the prescription drug market, smothering the competition that is needed to keep oversteps in check.

Specialty Pharmacies

Pharmacy Times

AUGUST 11, 2025

Transitions of care, or the movement of patients between health care settings or providers, impose a significant cost on the health care system due to frequent adverse events and hospital readmissions. 2 Although various programs aim to mitigate these risks, pharmacist-driven initiatives have proven particularly effective.

Hospitals

Pharmaceutical Technology

JULY 31, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmaceutical Technology

JULY 30, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Communication

Pharmacy Times

JULY 22, 2025

These third-party administrators act as intermediaries between drug manufacturers, pharmacies, and insurance companies. Furthermore, delays in medication access can exacerbate chronic conditions, such as diabetes, hypertension, and asthma, leading to increased hospitalization rates.

Mail-Order Pharmacies

Pharmaceutical Technology

AUGUST 12, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Immunization

Pharmaceutical Technology

JULY 21, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmacy Times

JULY 12, 2025

1 Howard’s team built their telehealth service in collaboration with hospitals and health systems, especially to tackle the issue of hospital readmissions for Medicare and Medicaid patients—each of which can cost hospitals thousands of dollars.

Independent Pharmacies

Pharmacy Times

JULY 21, 2025

The most common concerns include the following 1,3-5 : • Cost and insurance barriers: Affordability remains a major barrier, as patients have difficulty accessing CGMs due to high out-of-pocket costs or limited insurance coverage.

Compounding Pharmacies

Pharmaceutical Technology

JULY 29, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmaceutical Technology

JULY 25, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmaceutical Technology

JULY 24, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmaceutical Technology

JULY 23, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmacy Times

JULY 24, 2025

To me, it’s positioning this in terms of how quickly these patients benefit from it, and if it’s 7 days then in my opinion, start it in the hospital.” Still, despite enthusiasm, many pharmacists remain cautious about integrating finerenone into routine practice until it is formally approved and added to guidelines.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 25, 2025

John’s University – College of Pharmacy and Health Sciences and practices as an infectious diseases pharmacist at NYC Health + Hospitals/Elmhurst in Elmhurst, New York. Nicole Bradley, PharmD, BCPS, BCIDP, is an associate clinical professor at St.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 4, 2025

SHOW MORE Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization. The study's primary objective was to assess reversion rates to Humira, with 9% reverting after three months, while 91% remained on biosimilars or switched to alternatives.

Specialty Pharmacies

Pharmacy Times

JULY 1, 2025

Tafamidis, a selective transthyretin stabilizer, significantly reduces mortality and hospitalizations in ATTR-CM patients. Tafamidis] was compared to placebo and reduced all-cause mortality by 30% and [cardiovascular] hospitalizations by 32% over 30 months.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 23, 2025

Pharmacists are pivotal in patient counseling, therapy selection, and navigating insurance challenges, ensuring comprehensive diabetes management. She also noted the insurance considerations, including involvement with formularies and prior authorization, that come into play when making these decisions.

Insurance

Pharmacy Times

JULY 22, 2025

Personalized drug selection can lead to faster symptom control, fewer hospitalizations, and improved adherence—all of which contribute to better outcomes and a more streamlined care process. Beyond improving medication safety, pharmacogenetics enhances clinical efficiency by reducing the reliance on trial-and-error prescribing.

Compounding Pharmacies

Pharmacy Times

JUNE 16, 2025

Second, it does not address the core issues of higher prices, such as the use of rebates by insurers. Kennedy Jr, is permitted to develop a new rule that ties American drug prices to those of other nations. First, this may be blocked by a federal judge again. And finally, the most favored nation pricing model is unworkable.”—

Compounding Pharmacies

Pharmacy Times

JULY 28, 2025

Treatment selection is influenced by insurance, cost, and patient-specific factors due to the lack of direct RCT comparisons. 7 Based on a lack of head-to-head randomized clinical trials (RCTs), selection of the most appropriate VMAT2 inhibitor is routinely related to insurance approval, affordability, and patient-specific characteristics.

Compounding Pharmacies

Pharmaceutical Technology

JULY 31, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmacy Times

JUNE 17, 2025

That means that pharmacists in the twilight of their career have, at some point, filled a prescription, engaged in drug utilization review, filed insurance claims, and counseled per the Omnibus Budget Reconciliation Act of 1990 regulations for many of the products now found in front of the counter.

Compounding Pharmacies

Pharmacy Times

AUGUST 12, 2025

We connect patients with [teplizumab] compass navigators to help with insurance approvals in a copay program, logistics, and patient education. Pharmacy Times : How do pharmacists work with the broader care team to support teplizumab initiation and access Goldman: Pharmacists are care coordinators. You can find that online.

Specialty Pharmacies

Pharmaceutical Technology

JULY 4, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Chemotherapy

Pharmacy Times

JUNE 23, 2025

Goldman and Isaacs emphasize the importance of identifying at-risk patients through various health care touchpoints, including doctor's offices and pharmacies, and advocate for routine glucagon prescription and insurance coverage. But I also think everyone should have a ready-to-use cover on their insurance.

Compounding Pharmacies

Pharmacy Times

JULY 3, 2025

Getting this passed would mean broadening coverage within CMS, and then, hopefully, private insurers would follow suit. CMS leads the way when it comes to new therapies and approval, so hopefully, this means broadening access to both private and government-based insurers.

Compounding Pharmacies

Pharmacy Times

JULY 1, 2025

We look at multiple factors, including how stable their disease is, the number of flares patients have experienced, if any, and if they are at higher risk of further flares, hospitalizations, or disease progression.

Specialty Pharmacies

Pharmaceutical Technology

AUGUST 1, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmaceutical Technology

JULY 31, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

FDA

Pharmaceutical Technology

JULY 31, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging

Pharmacy Times

JULY 24, 2025

Someone ended up donating a car, and they used the money to buy tires and insurance. When patients get discharged from the hospital at night, they call her at home, and she comes in to fill their prescriptions. Loy-Helm jumped into action, mobilizing the staff and patients to raise money to buy her a car.

Independent Pharmacies